The 8 most recent market catalysts affecting $ELAN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 55
Elanco Animal Health Announces On-Time Completion Of 25K-Square-Foot Manufacturing Expansion Of Its Elwood, Kansas Manufacturing Site
Elanco Animal Health announced the on-time completion of a significant 25,000-square-foot expansion at its Elwood, Kansas manufacturing site. This expansion is crucial as it specif…
Aug 7, 2026
Corporate Catalyst
Neutral
Impact 55
Reported Earlier, FDA Issues Issues Emergency Use Authorization For Elanco's CLiK Extra Wound Spray For Prevention Of New World Screwworm Infestations
The FDA's Emergency Use Authorization for Elanco's CLiK Extra Wound Spray is a positive development for the company. This authorization allows Elanco to deploy its product quickly …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Elanco Animal Health, Raises Price Target to $33
UBS analyst Andrea Alfonso maintained a 'Buy' rating on Elanco Animal Health (ELAN) and raised the price target from $31 to $33. This action signals continued confidence from a pro…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Keybanc Maintains Overweight on Elanco Animal Health, Raises Price Target to $30
Keybanc analyst Steve Dechert maintained an 'Overweight' rating on Elanco Animal Health and raised the price target from $29 to $30. This action signals continued confidence in the…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
Elanco Sees Strong Pet Health Momentum, Bets on Innovative Products
Elanco's Q2 2026 results significantly exceeded expectations, with adjusted earnings of 34 cents against a 27-cent consensus and sales of $1.368 billion against $1.313 billion. Thi…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
Elanco Animal Health shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance above estimates. Also, the company issued Q3 sales guidance above estimates.
This headline represents a major positive corporate catalyst for Elanco Animal Health (ELAN). The combination of beating Q2 expectations, raising long-term guidance (FY26), and pro…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 75
Elanco Animal Health Sees Q3 Adj EPS $0.19-$0.22 vs $0.20 Est; Sees Sales $1.195B-$1.220B vs $1.192B Est
Elanco Animal Health (ELAN) released its Q3 adjusted EPS and sales guidance. The company's projected adjusted EPS range of $0.19-$0.22 has a midpoint of $0.205, which is slightly a…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
Elanco Animal Health Q2 Adj. EPS $0.34 Beats $0.27 Estimate, Sales $1.368B Beat $1.313B Estimate
Elanco's significant beat on both earnings per share and revenue estimates for Q2 suggests strong underlying demand for animal health products and effective cost management. This p…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.